10X Genomics Company Top Insiders

TXG Stock  USD 12.80  0.18  1.43%   
Roughly 75% of 10X Genomics' corporate insiders are selling. The analysis of insiders' sentiment of trading 10X Genomics stock suggests that many insiders are alarmed at this time. 10X Genomics employs about 1.3 K people. The company is managed by 19 executives with a total tenure of roughly 3048 years, averaging almost 160.0 years of service per executive, having 68.74 employees per reported executive.

Insider Sentiment 25

 Mostly Selling

 
Selling
 
Buying

Latest Trades

2025-05-22Serge SaxonovDisposed 9343 @ 8.3View
2025-02-24Serge SaxonovDisposed 5092 @ 11.07View
2025-02-21Alan MateoAcquired 40000 @ 11.14View
2024-08-22Serge SaxonovDisposed 6749 @ 22.53View
Monitoring 10X Genomics' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in 10X Genomics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest.
For more detail on how to invest in 10X Stock please use our How to Invest in 10X Genomics guide.

10X Genomics' Workforce Through the Years

Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with 10X Genomics' future performance. Based on our forecasts, it is anticipated that 10X will maintain a workforce of roughly 1310 employees by August 2025.
 
Covid

10X Genomics Management Team Effectiveness

The company has Return on Asset of (0.1243) % which means that on every $100 spent on assets, it lost $0.1243. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.2203) %, meaning that it generated no profit with money invested by stockholders. 10X Genomics' management efficiency ratios could be used to measure how well 10X Genomics manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -0.21. The current Return On Capital Employed is estimated to decrease to -0.26. At this time, 10X Genomics' Intangibles To Total Assets are most likely to slightly decrease in the upcoming years. The 10X Genomics' current Debt To Assets is estimated to increase to 0.12, while Non Current Assets Total are projected to decrease to roughly 230.2 M.
The current Common Stock Shares Outstanding is estimated to decrease to about 91.6 M. The current Net Loss is estimated to decrease to about (156.9 M)

10X Genomics Workforce Comparison

10X Genomics is rated second in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 5,626. 10X Genomics totals roughly 1,306 in number of employees claiming about 23% of equities under Health Care industry.

10X Genomics Profit Margins

The company has Net Profit Margin of (0.25) %, which means that it does not effectively control expenditures or properly executes on its pricing strategies. This is way below average. In the same way, it shows Net Operating Margin of (0.31) %, which entails that for every $100 of revenue, it lost $0.31.
Current ValueLast YearChange From Last Year 10 Year Trend
Gross Profit Margin0.850.6786
Significantly Up
Slightly volatile

10X Genomics Insider Trading History

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific 10X Genomics insiders, such as employees or executives, is commonly permitted as long as it does not rely on 10X Genomics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, 10X Genomics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Covid
Buy/Sell Ratio# Purchases Trades# Sales TradesTotal Shares PurchasedTotal Shares Sold
2025-06-01
1.2
6
5
 92,142 
 24,872 
2025-03-01
1.25
5
4
 515,891 
 67,607 
2024-12-01
0.4
2
5
 213,704 
 27,700 
2024-09-01
0.6667
2
3
 40,693 
 14,061 
2024-06-01
1.25
5
4
 43,245 
 12,325 
2024-03-01
0.3
3
10
 213,249 
 23,045 
2023-12-01
0.1538
2
13
 23,269 
 60,059 
2023-09-01
0.2105
4
19
 41,755 
 130,415 
2023-06-01
0.56
14
25
 4,029,578 
 4,047,038 
2023-03-01
2.0
12
6
 374,267 
 7,188 
2022-12-01
0.1818
2
11
 37,266 
 45,669 
2022-09-01
1.75
7
4
 280,621 
 14,994 
2022-06-01
1.8571
13
7
 58,776 
 36,824 
2022-03-01
0.3409
15
44
 671,063 
 472,894 
2021-12-01
0.1825
23
126
 456,038 
 743,581 
2021-09-01
0.1088
16
147
 250,998 
 538,475 
2021-06-01
0.1716
29
169
 2,264,126 
 2,550,880 
2021-03-01
0.1756
23
131
 362,052 
 446,082 
2020-12-01
0.2403
31
129
 6,519,448 
 8,683,593 
2020-09-01
0.1828
17
93
 348,054 
 2,983,500 
2020-06-01
0.4432
39
88
 14,228,985 
 21,519,808 
2020-03-01
0.3265
16
49
 17,490,797 
 21,119,567 
2019-12-01
1.0
5
5
 22,829 
 22,829 
2019-09-01
0.6866
46
67
 64,623,489 
 68,667,196 

10X Genomics Notable Stakeholders

A 10X Genomics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as 10X Genomics often face trade-offs trying to please all of them. 10X Genomics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting 10X Genomics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Adam TaichTreasurer, CFOProfile
James BryantDirector LegalProfile
Nikhil RaoDirector ManagementProfile
James WilburChief OfficerProfile
Mennah MoustafaChief OfficerProfile
Ruth BackerChief OfficerProfile
Florian BaumgartnerSenior ManagerProfile
Jonathan SchimmelVP OperationsProfile
Jim GoodrichChief OperationsProfile
Benjamin HindsonPresident, CoFounderProfile
Eric EsqChief OfficerProfile
Cassie CorneauManager FinanceProfile
Justin McAnearChief OfficerProfile
Jim WilburChief OfficerProfile
Jens DurruthyAssociate ManagementProfile
Alexander WongChief OfficerProfile
Michael SchnallLevinFounding CTOProfile
Serge SaxonovCEO CoFounderProfile
Rebecca PortChief OfficerProfile

About 10X Genomics Management Performance

The success or failure of an entity such as 10X Genomics often depends on how effective the management is. 10X Genomics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of 10X management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the 10X management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last ReportedProjected for Next Year
Return On Tangible Assets(0.20)(0.21)
Return On Capital Employed(0.24)(0.26)
Return On Assets(0.20)(0.21)
Return On Equity(0.26)(0.27)

10X Genomics Workforce Analysis

Traditionally, organizations such as 10X Genomics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare 10X Genomics within its industry.

10X Genomics Manpower Efficiency

Return on 10X Genomics Manpower

Revenue Per Employee467.7K
Revenue Per Executive32.1M
Net Loss Per Employee139.8K
Net Loss Per Executive9.6M
Working Capital Per Employee357.4K
Working Capital Per Executive24.6M

Complementary Tools for 10X Stock analysis

When running 10X Genomics' price analysis, check to measure 10X Genomics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy 10X Genomics is operating at the current time. Most of 10X Genomics' value examination focuses on studying past and present price action to predict the probability of 10X Genomics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move 10X Genomics' price. Additionally, you may evaluate how the addition of 10X Genomics to your portfolios can decrease your overall portfolio volatility.
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Stocks Directory
Find actively traded stocks across global markets
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Money Managers
Screen money managers from public funds and ETFs managed around the world
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules